TG Therapeutics, Inc. (NASDAQ:TGTX) Stake Raised by Summit Investment Advisors Inc.

Summit Investment Advisors Inc. raised its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 3.3% during the 4th quarter, HoldingsChannel reports. The fund owned 14,606 shares of the biopharmaceutical company’s stock after purchasing an additional 463 shares during the period. Summit Investment Advisors Inc.’s holdings in TG Therapeutics were worth $440,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. HighTower Advisors LLC grew its position in TG Therapeutics by 19.6% during the third quarter. HighTower Advisors LLC now owns 12,526 shares of the biopharmaceutical company’s stock valued at $294,000 after purchasing an additional 2,053 shares in the last quarter. Barclays PLC boosted its stake in shares of TG Therapeutics by 83.9% during the 3rd quarter. Barclays PLC now owns 347,057 shares of the biopharmaceutical company’s stock valued at $8,117,000 after buying an additional 158,323 shares during the period. Synovus Financial Corp acquired a new stake in shares of TG Therapeutics during the 3rd quarter valued at $465,000. Franklin Resources Inc. increased its stake in shares of TG Therapeutics by 3.8% in the third quarter. Franklin Resources Inc. now owns 128,985 shares of the biopharmaceutical company’s stock worth $2,945,000 after acquiring an additional 4,756 shares during the last quarter. Finally, Principal Financial Group Inc. raised its holdings in shares of TG Therapeutics by 1,549.4% during the third quarter. Principal Financial Group Inc. now owns 772,188 shares of the biopharmaceutical company’s stock worth $18,061,000 after acquiring an additional 725,371 shares in the last quarter. Institutional investors and hedge funds own 58.58% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have commented on TGTX. HC Wainwright restated a “buy” rating and issued a $55.00 target price on shares of TG Therapeutics in a research note on Tuesday, March 4th. StockNews.com raised TG Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, March 4th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, TG Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $40.67.

TG Therapeutics Stock Performance

TGTX opened at $38.32 on Friday. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59. The company has a market cap of $6.02 billion, a PE ratio of -383.16 and a beta of 2.14. The stock has a 50-day moving average of $36.34 and a 200-day moving average of $31.92. TG Therapeutics, Inc. has a 52-week low of $12.93 and a 52-week high of $43.32.

TG Therapeutics (NASDAQ:TGTX) last announced its earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.08 by $0.07. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The firm had revenue of $108.19 million during the quarter, compared to analysts’ expectations of $100.67 million. As a group, equities research analysts forecast that TG Therapeutics, Inc. will post 0.08 earnings per share for the current fiscal year.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.